Zymeworks (ZYME) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks Inc. has begun a Phase 1 clinical trial to test the safety and tolerability of ZW191, a new antibody-drug conjugate, in treating advanced cancers such as ovarian, endometrial, and non-small cell lung cancers. This trial marks a significant step for Zymeworks in their mission to provide innovative treatments for difficult-to-treat cancers. The study will enroll 145 patients globally, with the goal of advancing Zymeworks’ robust pipeline of therapeutic candidates.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.